Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist.

Gever JR, Soto R, Henningsen RA, Martin RS, Hackos DH, Panicker S, Rubas W, Oglesby IB, Dillon MP, Milla ME, Burnstock G, Ford AP.

Br J Pharmacol. 2010 Jul;160(6):1387-98. doi: 10.1111/j.1476-5381.2010.00796.x.

2.

Kinetic and thermodynamic assessment of binding of serotonin transporter inhibitors.

Martin RS, Henningsen RA, Suen A, Apparsundaram S, Leung B, Jia Z, Kondru RK, Milla ME.

J Pharmacol Exp Ther. 2008 Dec;327(3):991-1000. doi: 10.1124/jpet.108.142307. Epub 2008 Sep 18.

PMID:
18801948
3.

Antidepressants targeting the serotonin reuptake transporter act via a competitive mechanism.

Apparsundaram S, Stockdale DJ, Henningsen RA, Milla ME, Martin RS.

J Pharmacol Exp Ther. 2008 Dec;327(3):982-90. doi: 10.1124/jpet.108.142315. Epub 2008 Sep 18.

PMID:
18801947
4.

Structures that delineate orphanin FQ and dynorphin A pharmacological selectivities.

Reinscheid RK, Higelin J, Henningsen RA, Monsma FJ Jr, Civelli O.

J Biol Chem. 1998 Jan 16;273(3):1490-5.

5.

Interaction of [3H]orphanin FQ and 125I-Tyr14-orphanin FQ with the orphanin FQ receptor: kinetics and modulation by cations and guanine nucleotides.

Ardati A, Henningsen RA, Higelin J, Reinscheid RK, Civelli O, Monsma FJ Jr.

Mol Pharmacol. 1997 May;51(5):816-24.

PMID:
9145920
6.

Primary structure and tissue distribution of the orphanin FQ precursor.

Nothacker HP, Reinscheid RK, Mansour A, Henningsen RA, Ardati A, Monsma FJ Jr, Watson SJ, Civelli O.

Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8677-82.

7.

Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor.

Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, Grandy DK, Langen H, Monsma FJ Jr, Civelli O.

Science. 1995 Nov 3;270(5237):792-4.

PMID:
7481766
8.

Release of dopamine via the human transporter.

Eshleman AJ, Henningsen RA, Neve KA, Janowsky A.

Mol Pharmacol. 1994 Feb;45(2):312-6.

PMID:
7906856
9.

Contributions of conserved serine residues to the interactions of ligands with dopamine D2 receptors.

Cox BA, Henningsen RA, Spanoyannis A, Neve RL, Neve KA.

J Neurochem. 1992 Aug;59(2):627-35.

PMID:
1321233
10.

Pivotal role for aspartate-80 in the regulation of dopamine D2 receptor affinity for drugs and inhibition of adenylyl cyclase.

Neve KA, Cox BA, Henningsen RA, Spanoyannis A, Neve RL.

Mol Pharmacol. 1991 Jun;39(6):733-9.

PMID:
1828858
11.

Sodium-dependent isomerization of dopamine D-2 receptors characterized using [125I]epidepride, a high-affinity substituted benzamide ligand.

Neve KA, Henningsen RA, Kinzie JM, De Paulis T, Schmidt DE, Kessler RM, Janowsky A.

J Pharmacol Exp Ther. 1990 Mar;252(3):1108-16.

PMID:
2138666
12.

Functional characterization of a rat dopamine D-2 receptor cDNA expressed in a mammalian cell line.

Neve KA, Henningsen RA, Bunzow JR, Civelli O.

Mol Pharmacol. 1989 Sep;36(3):446-51.

PMID:
2571073

Supplemental Content

Loading ...
Support Center